{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:54:42Z","timestamp":1788260082786,"version":"build-2803163510"},"reference-count":47,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INTERREG VA, SEUPB","award":["BREATH INT-VA\/045"],"award-info":[{"award-number":["BREATH INT-VA\/045"]}]},{"DOI":"10.13039\/501100009697","name":"Hashemite University","doi-asserted-by":"publisher","award":["Personal PhD scholarship to Suhad Bani Melhim"],"award-info":[{"award-number":["Personal PhD scholarship to Suhad Bani Melhim"]}],"id":[{"id":"10.13039\/501100009697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,8,7]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Inflammation in cystic fibrosis (CF) airways is difficult to treat with well-established regimens often including azithromycin (AZ) as an immunomodulatory drug. As AZ has been reported to require CF transmembrane conductance regulator (CFTR) to be able to reduce interleukin (IL)-8 and given the emergence of highly effective CFTR \u201ctriple\u201d modulator therapy (elexacaftor\/tezacaftor\/ivacaftor; ETI), the aim of this study was to investigate the effect of AZ and ETI, singly and in combination, on ion channel activity and to assess the potential anti-inflammatory effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electrophysiological assessment of ETI and AZ was performed on three-dimensional cultures of primary CF human bronchial epithelial (HBE) cells using a Multi Trans-Epithelial Current Clamp. IL-8 from NuLi-1 (non-CF) and CuFi-1 (CF) cells treated with AZ was measured by ELISA. Inflammatory mediators from primary CF HBE cells exposed to tumour necrosis factor-\u03b1 in the presence of AZ, ETI and their combination, were screened using the Proteome Profiler\u2122 Human Cytokine Array Kit, with selected targets validated by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AZ did not alter CFTR chloride efflux, nor did it have any synergistic\/antagonistic effect in combination with ETI. AZ reduced IL-8 in NuLi-1 but not CuFi-1 cells. The Proteome Profiler\u2122 screen identified several disease-relevant cytokines that were modulated by treatment. Subsequent analysis by ELISA showed IL-8, IL-6, CXCL1 and granulocyte\u2013macrophage colony-stimulating factor to be significantly reduced by treatment with ETI, but not by AZ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Incorporating ETI into the standard of CF care provides an opportunity to re-evaluate therapeutic regimens to reduce treatment burden and safely discontinue chronic treatments such as AZ, without loss of clinical benefit. Identification of redundant treatments in the era of CFTR modulation may improve medication adherence and overcome potential adverse effects associated with the chronic use AZ and other drugs.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00502-2024","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:02:45Z","timestamp":1724346165000},"page":"00502-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis"],"prefix":"10.1183","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3413","authenticated-orcid":false,"given":"Suhad","family":"Bani Melhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-5409","authenticated-orcid":false,"given":"Lisa E.J.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-5198","authenticated-orcid":false,"given":"James A.","family":"Reihill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-0610","authenticated-orcid":false,"given":"S. Lorraine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2025011303503986000_10.6.00502-2024.1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/genes14101966","article-title":"Lung inflammatory genes in cystic fibrosis and their relevance to cystic fibrosis transmembrane conductance regulator modulator therapies","volume":"14","author":"Carbone","year":"2023","journal-title":"Genes (Basel)"},{"key":"2025011303503986000_10.6.00502-2024.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00946-2020"},{"key":"2025011303503986000_10.6.00502-2024.3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025011303503986000_10.6.00502-2024.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025011303503986000_10.6.00502-2024.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025011303503986000_10.6.00502-2024.6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.155259"},{"key":"2025011303503986000_10.6.00502-2024.7","doi-asserted-by":"publisher","DOI":"10.1039\/b810471a"},{"key":"2025011303503986000_10.6.00502-2024.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10910-0"},{"key":"2025011303503986000_10.6.00502-2024.9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008680"},{"key":"2025011303503986000_10.6.00502-2024.10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17476348.2021.2001333","article-title":"Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis","volume":"16","author":"Williamson","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"2025011303503986000_10.6.00502-2024.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2025011303503986000_10.6.00502-2024.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.12.023"},{"key":"2025011303503986000_10.6.00502-2024.13","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00198.2017"},{"key":"2025011303503986000_10.6.00502-2024.14","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"},{"key":"2025011303503986000_10.6.00502-2024.15","doi-asserted-by":"crossref","first-page":"e138722","DOI":"10.1172\/jci.insight.138722","article-title":"Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta","volume":"5","author":"Liessi","year":"2020","journal-title":"JCI Insight"},{"key":"2025011303503986000_10.6.00502-2024.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202106-1426OC"},{"key":"2025011303503986000_10.6.00502-2024.17","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.3390\/cells10113260","article-title":"Impact of airway inflammation on the efficacy of CFTR modulators","volume":"10","author":"Ribeiro","year":"2021","journal-title":"Cells"},{"key":"2025011303503986000_10.6.00502-2024.18","first-page":"Cd002203","article-title":"Macrolide antibiotics (including azithromycin) for cystic fibrosis","volume":"2","author":"Southern","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025011303503986000_10.6.00502-2024.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0628"},{"key":"2025011303503986000_10.6.00502-2024.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2347-4"},{"key":"2025011303503986000_10.6.00502-2024.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.10.027"},{"key":"2025011303503986000_10.6.00502-2024.22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1248\/bpb.b19-01091","article-title":"Azithromycin inhibits constitutive airway epithelial sodium channel activation in vitro and modulates downstream pathogenesis in vivo","volume":"43","author":"Fujikawa","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"2025011303503986000_10.6.00502-2024.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01403-10"},{"key":"2025011303503986000_10.6.00502-2024.24","doi-asserted-by":"publisher","DOI":"10.1080\/01902140802534967"},{"key":"2025011303503986000_10.6.00502-2024.25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2020.09.002","article-title":"An in vitro model for assessing drug transport in cystic fibrosis treatment: characterisation of the CuFi-1 cell line","volume":"156","author":"Sheikh","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"2025011303503986000_10.6.00502-2024.26","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00355.2002"},{"key":"2025011303503986000_10.6.00502-2024.27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg138"},{"key":"2025011303503986000_10.6.00502-2024.28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2025011303503986000_10.6.00502-2024.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.02.004"},{"key":"2025011303503986000_10.6.00502-2024.30","doi-asserted-by":"crossref","first-page":"A1450","DOI":"10.1016\/j.chest.2021.07.1327","article-title":"Increased cytokine levels define the airway of stable cystic fibrosis patients compared to healthy controls","volume":"160","author":"Zielonka","year":"2021","journal-title":"Chest"},{"key":"2025011303503986000_10.6.00502-2024.31","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.23.3.3949"},{"key":"2025011303503986000_10.6.00502-2024.32","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2004-0124TR"},{"key":"2025011303503986000_10.6.00502-2024.33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fphar.2017.00195","article-title":"Development of automated patch clamp technique to investigate CFTR chloride channel function","volume":"8","author":"Billet","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025011303503986000_10.6.00502-2024.34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jcf.2018.07.001","article-title":"R560S: A class II CFTR mutation that is not rescued by current modulators","volume":"18","author":"Awatade","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2025011303503986000_10.6.00502-2024.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.07.016"},{"key":"2025011303503986000_10.6.00502-2024.36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2015.11.003","article-title":"Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus","volume":"15","author":"Gianotti","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2025011303503986000_10.6.00502-2024.37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41231-016-0006-0","article-title":"Optimization of CFTR-mRNA transfection in human nasal epithelial cells","volume":"1","author":"Fern\u00e1ndez Fern\u00e1ndez","year":"2016","journal-title":"Trans Med Commun"},{"key":"2025011303503986000_10.6.00502-2024.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2025011303503986000_10.6.00502-2024.39","doi-asserted-by":"publisher","DOI":"10.1002\/PPUL.26261"},{"key":"2025011303503986000_10.6.00502-2024.40","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2025011303503986000_10.6.00502-2024.41","doi-asserted-by":"crossref","first-page":"e0304555","DOI":"10.1371\/journal.pone.0304555","article-title":"Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del","volume":"19","author":"Jarosz-Griffiths","year":"2024","journal-title":"PLoS ONE"},{"key":"2025011303503986000_10.6.00502-2024.42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1179\/joc.2005.17.4.385","article-title":"Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated cystic fibrosis transmembrane conductance regulator protein (CFTR)","volume":"17","author":"Labro","year":"2005","journal-title":"J Chemother"},{"key":"2025011303503986000_10.6.00502-2024.43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2372-2377.2005"},{"key":"2025011303503986000_10.6.00502-2024.44","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00078-09"},{"key":"2025011303503986000_10.6.00502-2024.45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1513\/AnnalsATS.202002-176OC","article-title":"Effect of concomitant azithromycin and tobramycin use on cystic fibrosis pulmonary exacerbation treatment","volume":"18","author":"Cogen","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025011303503986000_10.6.00502-2024.46","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jcf.2020.07.016","article-title":"Azithromycin and tezacaftor\/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis","volume":"20","author":"Song","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025011303503986000_10.6.00502-2024.47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00502-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:39:09Z","timestamp":1740375549000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00502-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1183\/23120541.00502-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00502-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}